Developing next-generation biomedical technologies, such as gene therapy and immunotherapy using cutting-edge solutions so those with NF2 live full and productive lives, free from daily physical and emotional pain or suffering. Connect patients for support, offering hope to patients & their families
Categories
Beneficiaries
NF2 is a genetic tumour disposition syndrome characterised by the development of central and peripheral nervous system tumours incl. schwannomas, meningiomas & ependymomas. Due to their multiplicity/anatomical location adjacent to highly eloquent structures, these tumours are usually managed conservatively with treatments of surgery/radiosurgery/chemotherapy . There is a significant unmet need of treatment options so patients can live their full lives.
In collaboration with the University of Manchester, we are supporting a number of research projects into NF2 tumours to find new & better treatment options, The outcome will extend quality of life and provide life extension. The work will contribute to Manchester’s existing world-leading NF2 tumour research programme. .The obvious benefits gained by patients are tumour control and prevention of intervention methods